Protein A chromatography remains the dominant capture step for monoclonal antibody (mAb) purification, but its cost is under increasing scrutiny as upstream titers rise and commercial manufacturing becomes increasingly cost-sensitive. Two main strategies can reduce capture cost: lowering upfront resin cost or extending usable resin lifetime.

This webcast will examine how these approaches influence effective cost per gram of purified antibody, with focus on key technical factors. Modelling analysis shows that the lowest-priced resin is not always the most economical option; rather, value depends on how well resin performance aligns with process needs, cleaning strategy, and campaign length. These findings support a more application-specific approach to Protein A resin selection to reduce cost of goods in commercial mAb manufacturing.

Attendees will gain insights into the technical factors that influence Protein A resin value, including alkaline stability, dynamic binding capacity, elution pH, and other process-specific considerations, to support more informed, application-specific resin selection

Key Takeaways:

• How lowering upfront resin cost and extending usable resin lifetime each influence effective cost per gram of purified antibody.
  
  
• Why the lowest-priced resin is not always the most economical option, and how performance, cleaning strategy, and campaign length affect true value.
  
  
• How an application-specific approach to Protein A resin selection can reduce cost of goods in commercial mAb manufacturing.